BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SciLifeLab - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SciLifeLab
X-ORIGINAL-URL:https://www.scilifelab.se
X-WR-CALDESC:Events for SciLifeLab
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220408T090000
DTEND;TZID=Europe/Stockholm:20220408T093000
DTSTAMP:20260527T160047
CREATED:20220330T131410Z
LAST-MODIFIED:20220330T132843Z
UID:10000574-1649408400-1649410200@www.scilifelab.se
SUMMARY:[Clinical Talks]Seeing is believing\, unraveling the discovery of a centimeter-long macro-bacteria
DESCRIPTION:On April 8\, Dr. Jean-Marie Volland\, Scientist at Berkeley Lab and Laboratory for Research in Complex Systems (LRC Systems)\, and Shailesh Date\, CEO of LRC Systems (Adj. Assoc. Professor at UCSF)\,will talk about their recent discovery and characterization of the macro-bacteria Ca. Thiomargarita magnifica. The threadlike single-cell bacterium\, commonly found in the Caribbean Mangroves\, is visible to the naked eye\, and able to grow up to 2 centimeters in length. In a recent effort\, an international team studied the “magnificent” organism using fluorescence\, x-ray\, and electron microscopy\, and fully sequenced the genome.  \n\n\n\nThrough a unique strategy of polyploidy\, along with compartmentalization of genomic material and protein synthesis in membrane-bound organelle\, the organism has been able to grow orders of magnitude over the theoretical limits for bacterial cells. The traditional view\, which has almost become dogmatic\, is that prokaryotes (bacteria and single-cell microbes) have free-floating DNA\, whereas eukaryotes (yeast and multicellular organisms) package their DNA in a nucleus. This new model organism blurs that line and offers amazing potential insights into biological evolutionary strategies\, many of which are as yet unexplored. One can only wonder at the type and number of new clinical innovations that will emerge as we continue exploring the frontiers of biology and biological complexity. \n\n\n\nRegister to receive zoom link\n\n\n\n  \n\n\n\n\n\n\n\nJean-Marie Volland is a Scientist at Lawrence Berkeley National Laboratory (Berkeley Lab) and at Laboratory of Research in Complex Systems (LRC Systems) in Menlo Park California. He obtained his PhD at the Université des Antilles\, in the French West Indies\, studying biology and tropical ecology in the Indian Ocean and Caribbean. Jean-Marie then continued to pursue his Postdoctoral research at University of Vienna\, Austria during 2012-2017. Initially in the Monika Bright´s Lab at the Department of Limnology and Biological Oceanography studying symbiosis in chemosynthetic ecosystems\, and then also in the Silvia Bulgheresi´s Lab at the Archea Biology and Ecogenomics Division studying tropical ecology pathways of microorganisms. In 2018 Jean-Marie joined the Berkeley Lab as an affiliate Scientist to continue working on uncovering highly divergent forms of life together with LRC Systems. The story of the discovery of Thiomargarita magnifica dates back a decade ago\, when marine biologist Olivier Gros\, from the Université of Antilles\, first discovered microbial filaments on leaves buried in the mangrove of Guadeloupe. Gros lab member and microbiologist colleague Silvina González-Rizzo identified it to be in fact be one bacterium. Jean-Marie\, together with his Université of Antilles colleagues and LRC Systems set forth to methodologically study and categorize the new organism. \n\n\n\n\n\n\n\nShailesh Date is the CEO and Founder of Laboratory for Research in Complex Systems (LRC Systems). He is also Adjunct Professor of Biology at San Francisco State University and an Associate Adjunct Professor of Epidemiology and Biostatistics at the University of California San Francisco (UCSF). Shailesh obtained his PhD at The University of Texas\, Austin in Molecular Biology in 2004\, and completed a postdoctoral fellowship at the University of Pennsylvania School of Medicine in 2008\, focusing on computational biology of infectious diseases. Between 2008-2015\, Shailesh worked as a scientist at Genentech\, and during a brief sabbatical in 2013\, completed the prestigious Ignite Program at the Stanford Graduate School of Business. He left Genentech in 2015 to join Global Viral (GV)\, a nonprofit organization with roots in public health research. He founded the LRC Systems in 2019\, transforming Global Viral into a new organization focused on complex systems research in a wide variety of areas. \n\n\n\nAbout Global Viral and LRC SystemsGlobal Viral was founded by Nathan Wolfe in 2007 as the Global Viral Forecasting Initiative (GVFI)\, focusing on public health and field epidemiology while supporting programs like HIV prevention run by USAID\, WHO and other similar organizations in Africa and South East Asia.In 2012\, the organization split into Metabiota\, a for-profit company that took over epidemiology and forecasting-related work\, and Global Viral\, a nonprofit that retained and concentrated on basic research.In 2019\, under the leadership of a new Chief Executive and a new board\, the organization reoriented its research towards complex systems and adopted the “Laboratory for Research in Complex Systems (LRC Systems)”\, which was initially founded as a new division within GV\, as its new name.https://www.lrc.systems \n\n\n\n\n\n\n\n\n“Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations . \n\n\n\nSeason 5\, will be held September 2021 until March 2022 with scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.
URL:https://www.scilifelab.se/event/seeing-is-believing-unraveling-the-discovery-of-ca-thiomargarita-magnifica-a-centimeter-long-macro-bacteria/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220318T090000
DTEND;TZID=Europe/Stockholm:20220318T093000
DTSTAMP:20260527T160047
CREATED:20220117T165753Z
LAST-MODIFIED:20220308T081854Z
UID:10000510-1647594000-1647595800@www.scilifelab.se
SUMMARY:True precision medicine in immuno-oncology\, challenges\, and opportunities
DESCRIPTION:Sara Mangsbo\, biträdande universitetslektor vid institutionen för farmaceutisk biovetenskap\, Immunonkologi.\n\n\n\n\n\nOn March 18\, Uppsala University Associate Professor Sara Mangsbo will talk about how the future of cancer therapy is becoming personal. Sara co-founded Strike Pharma to further develop the Uppsala University and SciLifeLab Drug Discovery platform co-developed ADAC technology (Adaptable Drug Affinity Conjugates).  \n\n\n\nWith current diagnostic tools also\, immunotherapy can and should enter the omics-field and the developed delivery platform envisions a truly patient tailored neoantigen cancer vaccine strategy\, ensuring that the body becomes the factory to generate tumor-specific T cells\, that can find and destroy tumor cells regardless of the location in the body. With a cost and time efficient “True Precision Medicine” approach\, tailored therapeutics will be a realistic future\, ultimately lowering the healthcare burden for a sustainable future. \n\n\n\nSara Mangsbo \n\n\n\nregister to receive zoom link\n\n\n\nSara Mangsbo is a Senior Lecturer in Antibody Drugs at Uppsala University at the Department of Pharmacy. She has her education background with a PhD in Clinical Immunology Uppsala University. Sara has since completed her postdoctoral studies at Leiden University Medical Center and started her own research group at Uppsala University in 2016. Her work focuses on the development and immunological characterization of novel immunotherapies and therapeutic combination strategies for drug discovery. Sara has previously also held a brand lead position in Immuno-oncology at Astra Zeneca’s marketing division and co-founded the drug development and service company startups Immuneed AB and VivoLogica AB (current board member). The drug development platform from Immuneed was acquired by the Norwegian pharmaceutical company Ultimovacs in 2018.  \n\n\n\nIn late 2020\, Sara co-founded Strike Pharma AB. Strike Pharma develops a novel next generation Antibody-Drug Conjugate (ADC) technology\, the ADAC technology. ADACs are short for Adaptable Drug Affinity Conjugates and are built to improve deliver tailored made synthetic peptides to specific cell types for improved immune modulation. Using the ADAC platform\, efficient delivery and extended half-life of patient tailored peptide therapeutics will ensure that the body becomes the factory\, producing billions of T cells that can find and destroy tumors cells regardless of the location in the body. \n\n\n\n\n\n\n\n\n\n\n\n“Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations . \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSeason 5\, will be held September 2021 until March 2022 with scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.
URL:https://www.scilifelab.se/event/true-precision-medicine/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220218T090000
DTEND;TZID=Europe/Stockholm:20220218T093000
DTSTAMP:20260527T160047
CREATED:20220117T165253Z
LAST-MODIFIED:20220117T171034Z
UID:10000509-1645174800-1645176600@www.scilifelab.se
SUMMARY:Spearheading the cardiovascular precision medicine with innovative medical tools
DESCRIPTION:On February 18\, we have invited Dr. Tero-Pekka Alastalo\, to give a talk about his experience with co-founding the precision medicine company Blueprint Genetics in 2012. What started out as a technology development spinout from Stanford University\, quickly grew to a global genetic testing company with >200 employees (acquired by Quest Diagnostics in 2020). With a solid background in pediatric cardiology and cardiovascular research\, Tero-Pekka recently joined CardioSignal by Precordior as the Chief Medicinal Officer and General Manager of the US operations. During his talk\, he will share his insights on how technology can revolutionize the medical methodology for a sustainable future and better use of resources. \n\n\n\nRegister to receive zoom link\n\n\n\n\n\n\n\nTero-Pekka Alastalo\, MD\, PhD\, is the Chief Medical Officer and General Manager of the US operations at CardioSignal by Precordior. He also co-founded Blueprint Genetics in 2012. Tero-Pekka obtained his MD\, PhD degree at the University of Turku in 2001. After 6 years of fellowships in pediatrics at the University of Turku\, he pursued his postdoctoral studies at Stanford University in basic research on cardiovascular biology and disease in the Marlene Rabinovitch Lab during 2007-2009. Upon returning to Finland\, he joined the University of Helsinki as a PI studying molecular and genetic mechanisms of cardiovascular diseases\, as well as a pediatric cardiology fellowship. In 2012 he joined forces with fellow Stanford postdoc Samuel Myllykangas to co-found Blueprint Genetics and held various management roles including Chief Medical Officer until September 2021\, when he joined CardioSignal. \n\n\n\nBlueprint Genetics is a genetic testing company focused on inherited diseases. With a patient-first mindset\, the company delivers high-quality genetic testing to the global clinical community (<4000 clinicians) across 15 medical specialties. Blueprint Genetics is based in Helsinki and Seattle\, with a customer base spanning over 70 countries. By combining a state-of-the-art laboratory process\, the latest sequencing technology\, AI empowered data-crunching tools and techniques\, world-class professionals\, and a holistic customer experience approach\, genetic knowledge is introduced to mainstream healthcare. Blueprint Genetics was acquired by Quest Diagnostics in 2020. \n\n\n\nCardioSignal by Precordior is a scientific forerunner in the field of cardiac motion sensing\, especially chest micro-rotation via micro-electromechanical sensors (MEMS) with some 30 scientific articles published in the area\, including in the prestigious journals Circulation and Nature Scientific Reports. The academic research studying the heart via chest micro-motions started at the University of Turku in January 2012. Continuing this work\, scientists at Precordior work today in close collaboration with researchers and cardiologists at several universities and hospitals. CardioSignal offers an easy and reliable detection of heart disease to people worldwide at an affordable price\, with an application that is accurate and reliable enough to serve physicians\, while easy and accessible enough to empower consumers. This is achieved via a smartphone application that transforms a phone into a device that can detect atrial fibrillation and\, in the future\, other heart conditions as well. \n\n\n\n\n\n\n\n\n\n“Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations . \n\n\n\nSeason 5\, will be held September 2021 until March 2022 with scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.
URL:https://www.scilifelab.se/event/spearheading-the-cardiovascular-precision-medicine-with-innovative-medical-tools/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220204T090000
DTEND;TZID=Europe/Stockholm:20220204T093000
DTSTAMP:20260527T160047
CREATED:20220117T164155Z
LAST-MODIFIED:20220117T171054Z
UID:10000508-1643965200-1643967000@www.scilifelab.se
SUMMARY:IMPRESS-Norway and implementing precision cancer medicine in Norway
DESCRIPTION:On February 4\, oncologist\, and Head of Research at Division of Cancer Medicine at Oslo University Hospital Professor Åslaug Helland will give a talk about her mission with the clinical precision medicine study IMPRESS-Norway that she co-founded in 2021. She is also a Professor at the University of Oslo. Åslaug is the PI of the IMPRESS-N study with the goal of “Improving public cancer care by implementing precision medicine in Norway\,” and it is a national clinical study for patients with advanced cancer after standard therapy\, with multiple Norwegian healthcare partners as well as industry collaborators. The effort is preparing Norway towards the many sustainable future benefits precision medicine has to offer for future healthcare solutions (Read more). \n\n\n\nregister to receive zoom link\n\n\n\nBiography \n\n\n\n\n\n\n\nÅslaug Helland\, MD\, PhD\, is a Group leader at the Institute for Cancer Research\, Norwegian Radium Hospital (NRH)\, Oslo\, Norway\, and Senior oncologist\, Dept of Oncology\, Oslo University Hospital\, Radiumhospital. She is also Professor at the University of Oslo Institute of Clinical Medicine. Åslaug obtained her MD degree in 1995\, and later her PhD in Medicine in 2000\, from the University of Oslo. She pursued her postdoctoral studies during 2003/2004 at Stanford University\, and in 2007/2008 as a visiting scientist at the Peter MacCallum Cancer Centre in Melbourne Australia\, adding to her international experience. Åslaugs research group focuses on translational studies on solid tumours\, with a special interest in pancreatic cancers\, lung cancers\, ovary cancers and colorectal cancers. They perform whole genome analyses on patient material\, aiming at identifying predictive and prognostic biomarkers as well as more targeted analyses for the identification of pathways and immune mechanisms of interest. By increasing the understanding of the underlying biology of tumour development\, they aim at improving cancer patient care. She furthermore led several clinical and translational studies in lung cancer. \n\n\n\nÅslaug is the PI of the IMPRESS-Norway study with the goal of “Improving public cancer care by implementing precision medicine in Norway\,” and it is a national clinical study for patients with advanced cancer after standard therapy. During 2019\, Oslo Cancer Cluster hosted a series of workshops with public and private stakeholders in cancer with the goal to accelerate the implementation of cancer precision medicine in Norway. The initial idea for IMPRESS emerged in one of these workshops. A dedicated team at Oslo University Hospital quickly turned it into a national effort together with colleagues at university hospitals across Norway. \n\n\n\nIMPRESS involves the active support of leading global pharmaceutical companies that will provide the study drugs and contribute with per patient fees. Public funding will help to ensure this innovative study paves the way for more cancer clinical trials in Norway. National infrastructure for precision diagnostics is needed and is currently being set up at all Norwegian cancer hospitals. Cancer patients who are eligible for clinical trials can soon be tested and selected based on their specific genetic profile. \n\n\n\n\n\n\n\n\n“Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations . \n\n\n\nSeason 5\, will be held September 2021 until March 2022 with scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.
URL:https://www.scilifelab.se/event/impress-norway-and-implementing-precision-cancer-medicine-in-norway/
LOCATION:Online event via Zoom
CATEGORIES:Event
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211126T090000
DTEND;TZID=Europe/Stockholm:20211126T093000
DTSTAMP:20260527T160047
CREATED:20211014T115823Z
LAST-MODIFIED:20211014T120713Z
UID:10000465-1637917200-1637919000@www.scilifelab.se
SUMMARY:Clinical Talks: The road towards precision medicine in Sweden
DESCRIPTION:On November 26\, we will host Karolinska Institutet (KI) Professor Richard Rosenquist Brandell. In addition to his academic research and clinical work\, he also co-founded the Genomic Medicine Sweden (GMS) initiative and serves as the Director of GMS. Richard will share his insights on Sweden’s national strategy to implement precision medicine into our healthcare environment and pave the way for the amazing potential the approach has to offer. To benefit from the sustainable advantages of tailored and efficient use of diagnostics and treatment options\, Sweden needs to prepare our society for the legal challenges and infrastructures necessary to support and enable this transformation. \n\n\n\nRead more about clinical talks\n\n\n\nRichard Rosenquist Brandell\, MD\, PhD\, is Professor of Clinical Genetics at Karolinska Institutet\, Senior Physician at Karolinska University Hospital and director of Genomic Medicine Sweden\, a national infrastructure for implementation of precision medicine. He obtained his MD degree in 1996\, and later his PhD in Medicine in 1998\, from Umeå University. In 2000 Richard joined Uppsala University Hospital (“Akademiska Sjukhuset”) and in 2007 became a Professor at the Department of Immunology\, Genetics and Pathology\, Uppsala University. In April 2017\, he relocated to the Karolinska University Hospital as a Senior Physician and Professor. Richard’s work focuses on hematological malignancies and utilizing high-throughput sequencing technologies\, his team has identified novel prognostic and predictive biomarkers that have significantly improved patient risk-stratification.  Dr Rosenquist Brandell is also a member of the Nobel Assembly at Karolinska Institutet. \n\n\n\nGenomic Medicine Sweden (GMS) started as a bottom-up initiative within the national Clinical Genomics Platform (previously named the Diagnostics Development platform) at the Swedish Science for Life Laboratory (SciLifeLab). In 2017 and 2018 discussions with funding agencies\, decision-makers\, healthcare providers\, patient organisations\, universities\, and industry led to the founding of GMS as a national venture. GMS strategic mission is to foster collaboration between healthcare providers\, academia\, patient organizations and industry and realize precision medicine by effectively utilizing the rapidly advancing sequencing technologies to provide the highest standards of genomic testing in routine clinical care throughout Sweden. \n\n\n\nRegistration
URL:https://www.scilifelab.se/event/clinical-talks-the-road-towards-precision-medicine-in-sweden/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2021/09/ClinicalTalks_Season5_twitter_1024.jpg
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211029T090000
DTEND;TZID=Europe/Stockholm:20211029T093000
DTSTAMP:20260527T160047
CREATED:20211014T115257Z
LAST-MODIFIED:20211028T115510Z
UID:10000464-1635498000-1635499800@www.scilifelab.se
SUMMARY:Clinical Talks: Blood-based methods for predicting the day of labor
DESCRIPTION:On October 29\, we will host a dual presentation with Dr. Ina Stelzer and Associate Professor Brice Gaudillière. At the Stanford School of Medicine Clinical Gaudillière laboratory\, Ina and Brice have developed a groundbreaking multi-omics approach to track the maternal metabolome\, proteome and immunome to predict exact labor onset. Estimating the time of delivery is of high clinical importance to minimize pre- and post-term deviations causing complications and suffering with ultimately more streamlined use of medical resources for a sustainable future. \n\n\n\n \n\n\n\nRead more about clinical talks\n\n\n\n\n\n\n\nIna is a molecular biologist and immunologist with an extensive background in pregnancy immunology. She obtained her PhD in Immunology 2017 from the University Medical Center Hamburg-Eppendorf (part of the University of Hamburg). Her work then focused on the immunology of pregnancy and feto-maternal immune crosstalk with a focus on fetal origin of disease development later in life. Ina is currently pursuing her postdoctoral research at Stanford University in the Gaudillière laboratory. Building on her expertise in preclinical (mouse) models of pregnancy and translational systems immunology\, her research leverages state-of-the-art single cell proteomic techniques (suspension and imaging mass cytometry) to study feto-maternal immune adaptations in healthy and pathological pregnancies with the goal to improving the health of mothers and their children. Her current K99/R00-funded work investigates the neuro-immune axis in normal pregnancy and the pathogenesis of pregnancy complications. While at Stanford during 2021\, Ina also recently completed the prestigious Stanford University Graduate School of Business organized Stanford Ignite certificate program. \n\n\n\n\n\n\n\nAssociate Professor Brice Gaudillière initially studied Engineering at Ecole Polytechnique in Paris before completing an MD-PhD degree from the Harvard-MIT Health Sciences and Technology program in 2009. During his postdoctoral fellowship at Stanford University in Dr. Garry Nolan’s laboratory\, he developed and standardized a pipeline to implement CyTOF in clinical studies. Brice is also a Board Certified Anesthesiologist and works clinically in the operating room 25% of his time. \n\n\n\nGaudilliere’s research group combines high parameter mass cytometry (suspension and imaging mass cytometry) with other proteomics approaches to study how the human immune system responds and adapts to physiological or pathological stressors. Ongoing studies in the Gaudilliere lab focus on several clinical scenarios including\, 1) surgical recovery and traumatic injury (NIGMS R35\, Stanford ITI\, Anesthesia department FIDL\, 2) pregnancy and preterm birth (Doris Duke Foundation\, Stanford Prematurity Center grants from the Bill and Melinda Gates and the March of Dimes Foundation\, 3) Host immune response to COVID-19 infection (FAST grant)\, 4) neurocognitive recovery after stroke (PHIND grant). \n\n\n\nregister here
URL:https://www.scilifelab.se/event/blood-based-methods-for-predicting-the-day-of-labor/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2021/09/ClinicalTalks_Season5_twitter_1024.jpg
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211021T170000
DTEND;TZID=Europe/Stockholm:20211021T173000
DTSTAMP:20260527T160047
CREATED:20210928T135950Z
LAST-MODIFIED:20211005T094033Z
UID:10000457-1634835600-1634837400@www.scilifelab.se
SUMMARY:Clinical Talks: Writing the Future
DESCRIPTION:Writing the Future\n\n\n\nOn October 21\, Dr. Emily Leproust will talk about her mission with co-founding Twist Bioscience\, and how their revolutionary oligosynthesis plattform is writing the future with DNA.  \n\n\n\nTwist Bioscience’s innovative silicon-based DNA Synthesis Platform is empowering our customers to realise their research goals faster. Twist offers DNA synthesis at an unmatched scale and price point\, without compromising on precision or quality. Here we discuss how DNA synthesis at scale can make traditional molecular biology approaches redundant in labs working with plasmid vectors; can power massive\, explicit diversity in CRISPR and antibody variant libraries; and can underpin NGS Target Enrichment Solutions with exceptional performance and unmatched speed in customisation. We’ll look at how these tools are helping drive innovation in a variety of research and application areas including cancer research\, drug discovery\, infectious disease and even data storage. \n\n\n\nAs an early pioneer in the high-throughput synthesis and sequencing of DNA\, Dr. Leproust is disrupting markets to enable the exponential growth of DNA-based applications including chemicals/materials\, diagnostics\, therapeutics\, food and digital data storage. In 2020\, BIO presented her with the Rosalind Franklin Award for Leadership. Foreign Policy named her one of their 100 Leading Global Thinkers and Fast Company named her one of the Most Creative People in Business. Prior to Twist Bioscience\, she held escalating positions at Agilent Technologies where she architected the successful SureSelect product line that lowered the cost of sequencing and elucidated mechanisms responsible for dozens of Mendelian diseases. She also developed the Oligo Library Synthesis technology\, where she initiated and led product and business development activities for the team. Dr. Leproust designed and developed multiple commercial synthesis platforms to streamline microarray manufacturing and fabrication. She serves on the Board of Directors of CM Life Sciences and is a co-founder of Petri\, an accelerator for start-ups at the forefront of engineering and biology. Dr. Leproust has published over 30 peer-reviewed papers – many on applications of synthetic DNA\, and is the author of numerous patents. She earned her Ph.D. in Organic Chemistry from University of Houston and her M.Sc. in Industrial Chemistry from the Lyon School of Industrial Chemistry. \n\n\n\nregistration\n\n\n\n\n\n\n\nSeason 5\, will be held September until December 2021 with scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community. \n\n\n\nAfter our recent planning hiatus\, we now have the great pleasure to announce that “Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations. \n\n\n\nRead more
URL:https://www.scilifelab.se/event/clinical-talks-writing-the-future/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2021/09/ClinicalTalks_Season5_twitter_1024.jpg
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211015T090000
DTEND;TZID=Europe/Stockholm:20211015T093000
DTSTAMP:20260527T160047
CREATED:20210921T171433Z
LAST-MODIFIED:20211014T114429Z
UID:10000450-1634288400-1634290200@www.scilifelab.se
SUMMARY:Clinical Talks: Playing your way to healthy life
DESCRIPTION:On October 15\, it’s our great pleasure to host Professor Emma Lundberg once again. This time she will focus her Talk on her innovative company Mindforce GameLab. With the Fig platform\, patients can via gamification transform into “playtients”\, people with medical conditions who enjoy playing games with a purpose to establish healthy habits. Fig guides you on the journey to better health\, including improved behavioral administration of medicals for intended and sustainable use. \n\n\n\nEmma Lundberg SciLifeLab. \nFoto © Daniel Roos\n\n\n\nEmma is a Professor in cell biology proteomics at KTH Royal Institute of Technology\, Sweden\, and Director of the Cell Atlas\, part of the Human Protein Atlas program. She spent two and half sabbatical years as visiting Associate Professor at Stanford School of Medicine and the Chan-Zuckerberg Biohub. In the interface between bioimaging\, proteomics and artificial intelligence her research aims to define the spatiotemporal organization of the human proteome at a subcellular level\, with the goal to understand how variations and deviations in protein expression patterns can contribute to cellular function and disease.  \n\n\n\nShe also has a keen interest\, passion\, and fascination in the use of gaming for science and health applications. This led Emma to start her own company in 2017\, Skellefteå based Mindforce Game Lab\, with the goal to unleash the powerful potential gamification could offer medical healthcare. Simply phrased\, medicines will not work if people do not take them. Despite this\, only every other person takes their medication as prescribed. This is a fundamental challenge for treating many chronic diseases\, in terms of patient outcomes\, as well as the overall burden on healthcare systems. Although there are products that help patients with extrinsic motivations\, such as reminders and notifications\, Mindforce Game Lab focuses on intrinsic motivations; designing games that build in feelings of companionship\, belonging and purpose. Patients learn how healthy routines\, such as sleeping well\, eating well\, exercising regularly\, and adhering to prescribed medication\, can improve feelings of well-being. This builds an inner driving force to want to change behaviour and to maintain a healthy lifestyle. In late 2020 Mindforce Game Lab joined the AstraZeneca BioVentureHub and relocated the development team to Gothenburg. \n\n\n\nRegister to receive zoom link\n\n\n\n\n\n\n\nAfter our recent planning hiatus\, we now have the great pleasure to announce that “Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations. \n\n\n\nRead more
URL:https://www.scilifelab.se/event/playing-your-way-to-healthy-life/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2021/09/ClinicalTalks_Emma-Lundberg_1024-1.jpg
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210930T170000
DTEND;TZID=Europe/Stockholm:20210930T173000
DTSTAMP:20260527T160047
CREATED:20210908T154652Z
LAST-MODIFIED:20210910T122137Z
UID:10000442-1633021200-1633023000@www.scilifelab.se
SUMMARY:Clinical Talks: Detect cancer early\, while it still can be cured
DESCRIPTION:On September 30\, Dr. Hyunsung John Kim\, will talk about the amazing potential RNA liquid biopsies can offer modern healthcare\, by detecting cancer early\, while it still can be cured. Resulting in a total transformation of cancer care\, ultimately allowing for a more efficient\, cost-effective\, and sustainable healthcare. While working as a senior Bioinformatician at Illumina\, John was part of the founding team who branched out GRAIL\, with its very promising Galleri multi-cancer early detection test soon to hit our Clinical reality.  \n\n\n\nRegister to receive zoom link\n\n\n\n\n\n\n\nJohn develops cloud computing tools that use machine learning and AI to generate biological insights from large clinically relevant datasets. He has worked in Next Generation Sequencing (NGS) and bioinformatics for over ten years in academic and industrial settings. \n\n\n\nHe started his career at the University of California at Santa Cruz where he received the Chancellor’s fellowship for designing new sequencing assays and algorithms for diagnostics and immunology. After receiving his PhD in Bioinformatics and Biomolecular Engineering\, John joined the Advanced Research group at Illumina. There he played a critical role in launching Illumina’s single cell product by developing the accompanying cloud-based bioinformatics software and was given the CEO award for his contributions. \n\n\n\nJohn departed from Illumina to make a significant impact on the fight against cancer by joining GRAIL Inc. as one of its founding members. At GRAIL\, he led a team of data scientists\, software engineers and statisticians as a bioinformatics technical lead. His team worked to gain a better understanding cell free nucleic acids and develop diagnostic products that detect cancer earlier than the current standard of care. John holds multiple patents and was an author on the first patent awarded to GRAIL. In addition\, he has co-authored peer-reviewed publications on his work related to the early cancer detection from cell free nucleic acids. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nClinical Talks Series\n\n\n\nAfter our recent planning hiatus\, we now have the great pleasure to announce that “Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations. \n\n\n\nRead more about the clinical talk series here\n\n\n\nSeason 5\, will be held September until December 2021 with a total of seven scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.
URL:https://www.scilifelab.se/event/clinical-talks-detect-cancer-early-while-it-still-can-be-cured/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2021/09/ClinicalTalks_Season5_twitter_1024.jpg
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210909T090000
DTEND;TZID=Europe/Stockholm:20210909T093000
DTSTAMP:20260527T160047
CREATED:20210903T140828Z
LAST-MODIFIED:20210906T140903Z
UID:10000438-1631178000-1631179800@www.scilifelab.se
SUMMARY:Clinical Talks: From BMC to Wall Street
DESCRIPTION:After our recent planning hiatus\, we now have the great pleasure to announce that “Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations. \n\n\n\nSeason 5\, will be held September until December 2021 with a total of seven scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community. \n\n\n\nRead more about the clinical talk series here\n\n\n\n\n\n\n\n\n \n\n\n\n\n\nDr. Andrea Ballagi\, Olink Proteomics VP Sales and Marketing \n\n\n\nAndrea Ballagi has an MD from Semmelweis School of Medicine in Budapest\, a PhD in Cancer research from Ludwig Institute for Cancer Research in Uppsala and a MBA from Uppsala University. She started her industry career at IDEXX Laboratories located in Switzerland as a general manager and later moved back to Uppsala as a global technical service and product line manager in 2011. Andrea joined Olink in 2012 as director of commercial operations and has since been a major part of the company’s expansive growth phases. She currently serves as VP Sales and Marketing EMEA. \n\n\n\nAndrea has with her roots as an MD a real passion to change the way diagnostics is being conducted to in today’s clinical reality. By bringing in groundbreaking technological possibilities and unprecedented future treatment options made possible by the extensive Olink technological platform. \n\n\n\n\n\n\n\n\n\n\n\n\n\nDr. Simon Fredriksson\, Co-Founder Olink \n\n\n\nSimon Fredriksson has a PhD in Molecular Medicine from Uppsala University and conducted postdoctoral studies in biochemistry at Stanford University\, and most recently appointed Adjunct Professor at KTH. He is also the co-founder of Olink\, and both former CSO\, and CEO of the company in its formation and growth phases. His academic research resulted in multiple high impact publications and inventions that were commercialized into products. Most notably the Proximity-Ligation and -Extension assays for multiplex protein detection\, the main products of Olink Proteomics. \n\n\n\nIn 2015\, Simon co-founded and was the former CEO of Genagon Therapeutics\, a ground-breaking immuno-oncology company. Presently co-founder and CEO of Pixelgen Technologies\, and Partner in Colibri Ventures\, a premier life science business incubator\, that helps start-ups develop early ideas into successful companies faster and more efficient. Simon also has extensive board member experience from 9 years at Olink AB (partly exited to Nexttobe 2011)\, Biolamina AB (+6 years)\, Olink Proteomics AB (exited to Summa Equity 2019)\, and Cartana AB (exited to 10X Genomics 2020) and Genagon Therapeutics. \n\n\n\nAs an experienced life science entrepreneur\, researcher and inventor spanning from research tools to bio-therapeutics\, Simon has always been fascinated by technology innovation capable of pushing the frontiers of scientific discovery into new and unchartered territories. \n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\nRegister to receive zoom link
URL:https://www.scilifelab.se/event/clinical-talks-from-bmc-to-wall-street/
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2021/09/ClinicalTalks_Season5_twitter_1024.jpg
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210909T090000
DTEND;TZID=Europe/Stockholm:20210909T093000
DTSTAMP:20260527T160047
CREATED:20210830T154920Z
LAST-MODIFIED:20210903T142012Z
UID:10000421-1631178000-1631179800@www.scilifelab.se
SUMMARY:Clinical Talks: From BMC to Wall Street
DESCRIPTION:After our recent planning hiatus\, we now have the great pleasure to announce that “Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations. \n\n\n\nSeason 5\, will be held September until December 2021 with a total of seven scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community. \n\n\n\nRead more about the clinical talk series here\n\n\n\n\n\n\n\n\n \n\n\n\n\n\nDr. Andrea Ballagi\, Olink Proteomics VP Sales and Marketing \n\n\n\nAndrea Ballagi has an MD from Semmelweis School of Medicine in Budapest\, a PhD in Cancer research from Ludwig Institute for Cancer Research in Uppsala and a MBA from Uppsala University. She started her industry career at IDEXX Laboratories located in Switzerland as a general manager and later moved back to Uppsala as a global technical service and product line manager in 2011. Andrea joined Olink in 2012 as director of commercial operations and has since been a major part of the company’s expansive growth phases. She currently serves as VP Sales and Marketing EMEA. \n\n\n\nAndrea has with her roots as an MD a real passion to change the way diagnostics is being conducted to in today’s clinical reality. By bringing in groundbreaking technological possibilities and unprecedented future treatment options made possible by the extensive Olink technological platform. \n\n\n\n\n\n\n\n\n\n\n\n\n\nDr. Simon Fredriksson\, Co-Founder Olink \n\n\n\nSimon Fredriksson has a PhD in Molecular Medicine from Uppsala University and conducted postdoctoral studies in biochemistry at Stanford University\, and most recently appointed Adjunct Professor at KTH. He is also the co-founder of Olink\, and both former CSO\, and CEO of the company in its formation and growth phases. His academic research resulted in multiple high impact publications and inventions that were commercialized into products. Most notably the Proximity-Ligation and -Extension assays for multiplex protein detection\, the main products of Olink Proteomics. \n\n\n\nIn 2015\, Simon co-founded and was the former CEO of Genagon Therapeutics\, a ground-breaking immuno-oncology company. Presently co-founder and CEO of Pixelgen Technologies\, and Partner in Colibri Ventures\, a premier life science business incubator\, that helps start-ups develop early ideas into successful companies faster and more efficient. Simon also has extensive board member experience from 9 years at Olink AB (partly exited to Nexttobe 2011)\, Biolamina AB (+6 years)\, Olink Proteomics AB (exited to Summa Equity 2019)\, and Cartana AB (exited to 10X Genomics 2020) and Genagon Therapeutics. \n\n\n\nAs an experienced life science entrepreneur\, researcher and inventor spanning from research tools to bio-therapeutics\, Simon has always been fascinated by technology innovation capable of pushing the frontiers of scientific discovery into new and unchartered territories. \n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\nRegister to receive zoom link
URL:https://www.scilifelab.se/event/from-bmc-to-wall-street-old/
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2021/08/Clinical-Talks.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
LOCATION:https://www.scilifelab.se/event/from-bmc-to-wall-street-old/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210903T090000
DTEND;TZID=Europe/Stockholm:20210903T093000
DTSTAMP:20260527T160047
CREATED:20210820T082759Z
LAST-MODIFIED:20220914T085524Z
UID:10000409-1630659600-1630661400@www.scilifelab.se
SUMMARY:Clinical Talks: Combining the power of nature with the efficiency of the chemical industry
DESCRIPTION:After our recent planning hiatus\, we now have the great pleasure to announce that “Clinical Talks” has been renewed for yet another exciting\, innovative\, and enlightening season. This season will focus on sustainable innovations within Life Sciences\, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations. \n\n\n\nSeason 5\, will be held September until December 2021 with a total of seven scheduled Talks\, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community. \n\n\n\nRead more about the clinical talk series here\n\n\n\n\n\n\n\n \n\n\n\n\n\nCombining the power of nature with the efficiency of the chemical industry\n\n\n\nKarim E. Cassimjee\, CEO & co-Founder EnginZyme \n\n\n\nRegister to receive zoom link\n\n\n\n\n\n\n\n\n\n\n\nKarim has a PhD in biotechnology from Royal Institute of Technology (KTH) and conducted postdoctoral studies in organic chemistry and quantum mechanics at Arrhenius laboratory (Stockholm University). He early found a passion for enzymes and their potential for solving the commonly unsustainable production of the chemical products used in our everyday lives and that modern society relies upon. He co-founded EnginZyme in 2014 – a company dedicated to replacing the incumbent chemical transformations that rely on heavy metal catalysts and high energy consumption\, and produce a lot of bi-products. This is accomplished by developing production processes based on a proprietary and general enzyme immobilization technology applied in flow chemistry set-ups. In 2021 Karim was selected as the KTH Alumnus of the Year\, and EnginZyme as Technology Pioneer by the World Economic Forum. \n\n\n\nDuring the first Clinical Talks of the season\, Karim will share his passion and insights for his work\, technology aspirations\, and experiences in pharmaceutical production\, and how EnginZyme will “make the impossible possible” for a sustainable industrial large-scale production for future generations.”
URL:https://www.scilifelab.se/event/clinical-talks-combining-the-power-of-nature-with-the-efficiency-of-the-chemical-industry/
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2021/08/Clinical-Talks.png
ORGANIZER;CN="Clinical Talks":MAILTO:precisionmedicine@scilifelab.se
LOCATION:https://www.scilifelab.se/event/clinical-talks-combining-the-power-of-nature-with-the-efficiency-of-the-chemical-industry/
END:VEVENT
END:VCALENDAR